Targeting ferroptosis opens new avenues for the development of novel therapeutics

被引:181
|
作者
Sun, Shumin [1 ]
Shen, Jie [1 ]
Jiang, Jianwei [1 ]
Wang, Fudi [1 ]
Min, Junxia [1 ]
机构
[1] Zhejiang Univ, Affiliated Hosp 1, Affiliated Hosp 2,Sch Med, Inst Translat Med,Canc Ctr,Sch Publ Hlth,State Ke, Hangzhou, Peoples R China
基金
中国国家自然科学基金;
关键词
GLUTATHIONE-PEROXIDASE; 4; ERASTIN-INDUCED FERROPTOSIS; POLYUNSATURATED FATTY-ACIDS; TRANSFERRIN-BOUND-IRON; CELL-DEATH MECHANISMS; LIPID-PEROXIDATION; SMALL-MOLECULE; CANCER-CELLS; IN-VIVO; MITOCHONDRIAL DYSFUNCTION;
D O I
10.1038/s41392-023-01606-1
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Ferroptosis is an iron-dependent form of regulated cell death with distinct characteristics, including altered iron homeostasis, reduced defense against oxidative stress, and abnormal lipid peroxidation. Recent studies have provided compelling evidence supporting the notion that ferroptosis plays a key pathogenic role in many diseases such as various cancer types, neurodegenerative disease, diseases involving tissue and/or organ injury, and inflammatory and infectious diseases. Although the precise regulatory networks that underlie ferroptosis are largely unknown, particularly with respect to the initiation and progression of various diseases, ferroptosis is recognized as a bona fide target for the further development of treatment and prevention strategies. Over the past decade, considerable progress has been made in developing pharmacological agonists and antagonists for the treatment of these ferroptosis-related conditions. Here, we provide a detailed overview of our current knowledge regarding ferroptosis, its pathological roles, and its regulation during disease progression. Focusing on the use of chemical tools that target ferroptosis in preclinical studies, we also summarize recent advances in targeting ferroptosis across the growing spectrum of ferroptosis-associated pathogenic conditions. Finally, we discuss new challenges and opportunities for targeting ferroptosis as a potential strategy for treating ferroptosis-related diseases.
引用
收藏
页数:30
相关论文
共 50 条
  • [41] Ferroptosis and Alzheimer's: unveiling new avenues for the treatment and prevention
    Sharma, Veerta
    Sharma, Prateek
    Singh, Thakur Gurjeet
    METABOLIC BRAIN DISEASE, 2025, 40 (04)
  • [42] Targeting glutamatergic transmission in the development of novel therapeutics for mood and anxiety disorders
    Sanacora, G.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2013, 23 : S142 - S142
  • [43] q Serial Femtosecond Crystallography Opens New Avenues for Structural Biology
    Coe, Jesse
    Fromme, Petra
    PROTEIN AND PEPTIDE LETTERS, 2016, 23 (03): : 255 - 272
  • [44] Targeting DNA Replication and Repair for the Development of Novel Therapeutics against Tuberculosis
    Reiche, Michael A.
    Warner, Digby F.
    Mizrahi, Valerie
    FRONTIERS IN MOLECULAR BIOSCIENCES, 2017, 4
  • [45] Development and translation of novel therapeutics targeting tumor-associated macrophages
    Kosoff, David
    Lang, Joshua M.
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2019, 37 (08) : 556 - 562
  • [46] STRUCTURAL FOAM IN SMALL PARTS OPENS NEW CHALLENGES AND PROFIT AVENUES
    TORTOLAN.FW
    PLASTICS WORLD, 1974, 32 (10): : 56 - 59
  • [47] Cholesterol-ferroptosis nexus: Unveiling novel cancer therapeutic avenues
    Lee, Jaewang
    Roh, Jong-Lyel
    CANCER LETTERS, 2024, 597
  • [48] Inhibiting Ferroptosis: A Novel Approach for Ulcerative Colitis Therapeutics
    Huang, Jinke
    Zhang, Jiaqi
    Ma, Jinxin
    Ma, Jing
    Liu, Jiali
    Wang, Fengyun
    Tang, Xudong
    OXIDATIVE MEDICINE AND CELLULAR LONGEVITY, 2022, 2022
  • [49] New avenues for NASH therapy by targeting ACC
    Bian, Huijie
    Liu, Ye-Mao
    Chen, Zhi-Nan
    CELL METABOLISM, 2022, 34 (02) : 191 - 193
  • [50] PARTICIPATION IN DEVELOPMENT - NEW AVENUES
    GOULET, D
    WORLD DEVELOPMENT, 1989, 17 (02) : 165 - 178